The absolute oral bioavailability and pharmacokinetics of clindamycin administered to 16 healthy volunteers and 16 patients with AIDS were compared. Clindamycin was given intravenously (i.v.) (Cleocin phosphate) at a dose of 600 mg as a 25-min infusion and orally (Cleocin hydrochloride) by use of a crossover design in both study groups. Plasma samples were analyzed by gas-liquid chromatography. Plasma drug clearance and volume of distribution at the steady state following the i.v. dose differed between study groups. The clearances were 0.27 0.06 liter/h/kg in healthy volunteers and 0.21 0.06 liter/h/kg in AIDS patients (P = 0.014; Mann-Whitney U test); the volumes of distribution at the steady state were 0.79 + 0.13 and 0.66 0.12 liter/kg in healthy volunteers and AIDS patients, respectively (P = 0.005). The elimination half-life did not differ between the two groups. The bioavailability of clindamycin capsules in AIDS patients was approximately 1.5 times that in healthy volunteers (0.53 + 0.14 versus 0.75 + 0.20; P = 0.002). Peak concentrations following the oral dose were higher in AIDS patients as well (7.7 2.5 versus 5.3 1.0 mg/liter, P = 0.0008). Three AIDS patients experienced severe diarrhea following the oral dose; four patients had mild diarrhea following the i.v. dose. No adverse effects were reported by the healthy volunteers. The pharmacokinetic parameters observed in this study for AIDS patients may be useful for the consideration of clindamycin dosage regimens in patients treated for toxoplasmic encephalitis. These findings suggest that the effect of AIDS on drug disposition deserves further investigation, particulariy for orally administered drugs.
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Toxoplasmic encephalitis (TE) is considered the most common cause of intracerebral mass lesions in patients with AIDS, occurring in 3 to 40% of AIDS patients (16) . Standard therapy for TE includes the synergistic combination of pyrimethamine and sulfadiazine, which provides a sequential blockade of folic acid metabolism. However, many patients with AIDS are unable to complete a course of therapy because of adverse reactions (18) .
Clindamycin has been used either alone or more frequently in combination with pyrimethamine to treat TE in patients with AIDS who develop untoward side effects to the sulfonamide component of the standard pyrimethaminesulfadiazine therapy (4, 10, 15, 21, 23, 24) . Recently, the results of an international prospective study comparing the combinations pyrimethamine-sulfadiazine and pyrimethamine-clindamycin suggest that the relative efficacies of the two combination treatments are approximately equal (3) .
The activity of clindamycin against Toxoplasma gondii is controversial: clindamycin was effective in a murine model of TE (11) but was ineffective in a model based on Taxoplasma-infected rat monocytes (9) . Clindamycin does not penetrate adequately into cerebrospinal fluid, even in the presence of bacterial meningitis (7); however, it has been suggested that damage of the blood-brain barrier in AIDS patients, involving marked tissue destruction and inflammation, may allow clindamycin to reach effective levels in the brain (11) . The exact role of clindamycin in the treatment of TE is still under investigation. Nevertheless, since clinical improvement and radiologic improvement have been reported in most cases, clindamycin is currently given to AIDS patients both intravenously (i.v.) as treatment for acute illness and orally as suppressive therapy for chronic illness to prevent a relapse.
Few reports are available on the effect of AIDS on drug disposition (5, 22) . Absorption and oral bioavailability may be primarily altered in AIDS patients because of the profound abnormalities of the gastrointestinal tract that characterize AIDS (13) . In addition, other differences in the overall pharmacokinetics of a drug due to AIDS may not be excluded a priori. The aim of this study was to compare clindamycin pharmacokinetics in AIDS patients and healthy subjects after i.v. and oral administration of clindamycin. All subjects were asked to fast for 10 h before and 2 h after oral and i.v. drug administration. Standard meals were provided during each study day. Subjects had to abstain from alcoholic beverages for 2 days before and during each study day. No caffeine-containing beverages were allowed for 1 day before and during each study day.
MATERIALS AND METHODS

Subjects
Blood samples (7 ml) were collected for each of the treatment regimens in the following manner: treatment A, 0 (predose) Analytical methods. Plasma clindamycin levels were determined by use of a capillary column gas-liquid chromatographic assay. Clindamycin hydrochloride and a structural analog used as an internal standard (U-33232E) were provided by The Upjohn Co.
Sample preparation involved liquid-liquid partitioning with back extraction (ethyl acetate at a basic pH followed by water at an acidic pH and then chloroform at a basic pH) and derivatization with heptafluorobutyric anhydride (catalog no. 15,739-2; Aldrich Chemical Co., Milwaukee, Wis.).
The final clindamycin derivative was injected onto an HP5890 gas-liquid chromatograph equipped with an automatic injector, a W-17 fused-silica capillary column, and an electron capture detector. Helium (zero grade) (LCCO, Chicago, Ill.) was used as the carrier gas (flow rate, 2 cm3/min), and nitrogen (zero grade) (LCCO) was used as the make-up gas (flow rate, 35 to 40 cm3/min). Injector and detector temperatures were 225 and 350°C, respectively. A two-step temperature gradient (165 to 200°C and then 200 to 250°C) was used.
The standard curve (range, 25 to 750 ,ug/liter) was fitted to a weighted quadratic equation (y = ax2 + bx + c; weight = l/y) by use of an SAS language program (26) . Interday and intraday variabilities were 8.2 and 3.2%, respectively, at a concentration of 75 ,ug/liter (n = 9). The accuracies, calculated as (1 -[average calculated concentration/spiked concentration]) x 100, were 3.9 and 6.9% at concentrations of 75 ,ug/liter (n = 9) and 350 ,ug/liter (n = 9), respectively.
An evaluation of the effect of a human immunodeficiency virus deactivation procedure (heat deactivation at 56 to 58°C for 35 to 45 min) on clindamycin stability was done by comparing the peak height ratios obtained from a chromatographic analysis of deactivated and control plasma samples spiked with 75, 200, and 500 ,ug of clindamycin per liter. No statistical differences (paired t test) were found.
The effect of dilution on clindamycin concentration determinations was evaluated at concentrations in plasma of 5 mg/liter (dilutions, 1:40, 1:20, and 1:10) and 10 mg/liter (dilutions, 1:40 and 1 :20) . No differences were found in the calculated concentrations (P < 0.05; paired t test).
Plasma samples for both i.v. and oral doses for each subject were analyzed on the same day. All samples obtained from healthy volunteers and AIDS patients were heat deactivated and analyzed alternately throughout the study.
No interference with compounds administered concomitantly to AIDS patients was detectable by observation of the predose plasma sample chromatograms.
Pharmacokinetic analysis. Clindamycin pharmacokinetic parameters were determined by noncompartmental methods (8) .
The area under the plasma concentration-time curve (AUC) from time zero to infinity was calculated by use of the linear and logarithmic trapezoidal rules in the ascending and decaying phases of the curve, respectively. Clearance (CL) was calculated as the AUC following i.v. infusion 
RESULTS
Demographic data for AIDS patients and healthy volunteers are shown in Table 1 .
The mean plasma concentration-time profiles obtained for healthy volunteers and AIDS patients following oral administration are shown in Fig. la, The values that we found for plasma CL, V.,, and t1/2 were comparable to the values reported in other studies that used assays specific for clindamycin (6, 20) .
The most interesting finding emerging from this study is the bioavailability of clindamycin in AIDS patients, which was approximately 1.5 times that found in healthy volunteers. Assay error of up to 10% may account for the observed bioavailability values being higher than 1 in three AIDS patients. Another explanation may be evidenced by the fact that clindamycin is administered i.v. as a phosphate ester. Clindamycin phosphate is rapidly hydrolyzed in serum to clindamycin base, with a tj/2 of 10 min and a recovery in the urine of approximately 0.35% (20) . Therefore, we assumed for our calculation a bioavailability value of 1 for clindamycin from clindamycin phosphate. However, clindamycin phosphate may be eliminated unchanged in the bile, a possibility that could result in an oral bioavailability value higher than 1.
The observation of a higher bioavailability value in AIDS patients than in healthy volunteers was unexpected, since (14) . specimens have been reported (5) . Therefore, the bioavailConsequently, an explanation for the higher bioavailability ability of orally administered drugs is assumed to be normal values for clindamycin in AIDS patients may be based on a (Fig. la) .
The variability in pharmacokinetic parameters observed for AIDS patients was comparable to that observed for healthy volunteers, despite the larger range of clinical variability in the patient population. An attempt was made to correlate the concomitant intake of drugs as well as the clinical parameters for the patients to pharmacokinetic parameters. Clindamycin pharmacokinetic parameters did not correlate with the concomitant intake of other drugs. Furthermore, no correlation was found between F values and a history of diarrhea or a diagnosis of an opportunistic infection of the gastrointestinal tract, such as giardiasis or cryptosporidiosis. No correlation was found between CL values and a history of hepatitis B or A. The following patients with abnormal laboratory values were enrolled in the study (see inclusion criteria): patients 2, 3, and 5 had elevated aspartate aminotransferase and alanine aminotransferase levels, patient 10 had elevated gamma-glutamyl aminotransferase levels; patients 6, 7, 10, 12, and 13 had low leukocyte counts; and patients 3, 6, 7, 10, 12, 13, and 15 had low erythrocyte counts. It is noteworthy that all the patients with the highest bioavailability values (except for patient 8) had low erythrocyte counts.
The clinical relevance of our observations may be only speculated on, since it is not known whether plasma clindamycin levels are correlated with clinical efficacy against cerebral toxoplasmosis and with toxicity. The observed lower V,, values might be regarded as a negative factor for tissue penetration. On the other hand, the observed higher peak concentration and bioavailability values might suggest a higher concentration at the effect site (here, primarily the brain). Clindamycin toxicity in AIDS patients is probably related primarily to disease state rather than to levels in plasma. The patients who experienced severe diarrhea in this study did not have the highest peak concentration or bioavailability values.
In conclusion, the bioavailability and pharmacokinetics of clindamycin in AIDS patients and healthy volunteers were compared. Higher bioavailability, lower plasma CL, and lower V,, values in AIDS patients relative to healthy volunteers were observed. The data from this study may be useful in the consideration of treatment regimens to be adopted for clindamycin in the therapy of cerebral toxoplasmosis in AIDS patients. Our data suggest that the effect of AIDS on drug pharmacokinetics deserves further investigation, especially for orally administered compounds.
